President – ABCSG

Breast cancer remains a scourge of humanity, one out of eight women being affected – and that is too much. Carrying out clinical trials serves to procure treatment success.

Dr. Gnant has been serving as President, Austrian Breast & Colorectal Cancer Study Group (ABCSG), since November 2005. Since its inception, the ABCSG has been a caregiver to some 22,000 trial participants recruited and treated at 100 centers across Austria. The Group has specialized in research in breast and bowel cancer. The objective is to standardize and continuously improve cancer diagnosis and treatment in this country by means of clinical science.

www.abcsg.at

 

As Group President, I am pleased …

  • To improve healthcare in Austria
  • To amplify efficient healing
  • To contribute to global success in terms of breast cancer
  • To be an example for other physicians
  • To give significance to Austria

 

Interviews on scientific highlights

Elsevier Global Medical News/OncologyStat interviews Dr. Michael Gnant on the Austrian Breast and Colorectal Cancer Study Group-12 trial. The study assessed use of zoledronic acid to prevent breast cancer recurrence in postmenopausal women. Interviewer: Mary Ellen Schneider, EGMN.

This is a YouTube interview with Dr. Gnant on the occasion of the 2008 ASCO Annual Meeting.

 

 

Prof. Michael Gnant, Medical University of Vienna on ecancer tv. Zoledronic acid added to adjuvant endocrine therapy prevents pre-menopausal breast cancer recurrences.

Click here for a press conference clipping with Dr. Gnant on ecancer tv.